title: Regulatory advice on evaluation of the proarrhythmic potential of drugs.
authors.affiliation: US Food and Drug Administration, DA, Rockville, MD 20857, USA. stockbridgen@cder.fda.gov
authors.forename: Norman
authors.initials: N
authors.lastname: Stockbridge
authors.forename: Douglas C
authors.initials: DC
authors.lastname: Throckmorton
mesh_terms: D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D002170:Canada; D004341:Drug Evaluation; D004353:Drug Evaluation, Preclinical; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence; D064420:Drug-Related Side Effects and Adverse Reactions; D004562:Electrocardiography / Q000187:drug effects; D006801:Humans; D007473:Ion Channels / Q000187:drug effects; D011358:Product Surveillance, Postmarketing; D012307:Risk Factors; D014481:United States
chemical_list: D007473:Ion Channels